Diabetes Mellitus Clinical Trial
Official title:
Changes of the Endothelial Glycocalyx, the Elastic Properties of the Arteries and the Coronary Flow Reserve (CFR) During Oral Glucose Tolerance Test in Patients With New Onset Diabetes Mellitus and First-degree Relatives
Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity. The association between damage of endothelial glycocalyx, impaired arterial elastic properties, and CFR in diabetics and first degree relatives has not been explored. The purpose of this study is to explore the association between damage of endothelial glycocalyx, impaired arterial elastic properties, and CFR in diabetics and first-degree relatives before and after during oral glucose tolerance test (OGTT).
The investigators plan to examine 90 subjects without known diabetes a standard 75-gr oral
glucose tolerance test (OGTT) will be performed. [30 first degree relatives of diabetics with
normal OGTT (relatives), 30 with normal OGTT and no family history of diabetes (normals), and
30 with abnormal OGTT (diabetics) matched for age and sex].
Plasma glucose and serum insulin levels will be measured in venous blood collected at 0, 30,
60, 90 and 120min after glucose loading. At the same time intervals, the investigators will
measure:
1. the carotid to femoral pulse wave velocity (PWVc) using the Complior apparatus
2. the aortic pulse wave velocity (PWVa), central systolic blood pressure (cSBP) and
augmentation index (AI) using an oscillometric method (Arteriograph,TensioMed) as
markers of arterial stiffness and wave reflections
3. the coronary flow reserve (CFR) at baseline and after adenosine infusion (140 μg × kg-1
× min-1) for 3 minutes to assess coronary vasomotor function
4. the perfusion boundary region (PBR- micrometers) of the sublingual arterial microvessels
(ranged from 5-25 micrometers) using Sideview Darkfield imaging (Microscan, Glycocheck).
Increased PBR is considered an accurate non invasive index of reduced endothelial
glycocalyx thickness.
In addition, the investigators will measure free fatty acids, triglycerides, glycerol, C
reactive protein (CRP), transforming growth factor-b (TGF-b), Lipoprotein-Associated
Phospholipase A2, (LP-LPA2), tumor necrosis factor (TNF-a), interleukin 6 (IL6) and
interleukin 10 (IL10) propeptide of type I procollagen, (PIP), propeptide of procollagen type
III (PIIINP), matrix metallopeptidases 9 and 2 (MMP 9 and 2), macrophage-colony stimulating
factor ( MCSF).
The investigators will measure insulin resistance a) after fasting, using homeostatic model
assessment (HOMA) and hepatic insulin sensitivity (HIS) b) during oral glucose tolerance test
(OGTT) using Matsuda index and insulin sensitivity index (ISI). The investigators will
categorize patients in those with normal (<140 mg/dl at 120 min) and those with abnormal OGTT
(>200mg/dl at 120min).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |